Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors.

Cancer biology & therapy - 1 May 2007

Yuza Yuki, Glatt Karen A, Jiang Jingrui, Greulich Heidi, Minami Yuko, Woo Michele S, Shimamura Takeshi, Shapiro Geoffrey, Lee Jeffrey C, Ji Hongbin, Feng Whei, Chen Tzu-Hsiu, Yanagisawa Haruhiko, Wong Kwok-Kin, Meyerson Matthew

Abstract excerpt

Targeted cancer therapies impede cancer cell growth by inhibiting the function of activated oncogene products. Patients with non-small cell lung cancer and somatic mutations of EGFR can have a dramatic response to treatment with erlotinib and gefitinib; different somatic mutations are associated with different times to progression and survival. In this study, the relative and absolute potencies of two distinct...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Survival
Share to Erlotinib Hydrochloride

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Peptide Fragments

Share to Precursor Cells, B-Lymphoid

Share to Quinazolines

Share to Quinolines

Share to Retroviridae

Share to Sequence Deletion

Source

Identifiers

PMID: 17495523
DOI: 10.4161/cbt.6.5.4003

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors.PMID 17495523Read ↗

The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.Semantic proximity Read ↗

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.Semantic proximity Read ↗

EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase InhibitorsSemantic proximity Read ↗

TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR MutationsSemantic proximity Read ↗

Defining the Sensitivity Landscape of 74,389 EGFR Variants to Tyrosine Kinase InhibitorsSemantic proximity Read ↗

Defining the Sensitivity Landscape of 74,389 EGFR Variants to Tyrosine Kinase InhibitorsSemantic proximity Read ↗

Kinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: moving past common point mutations or indels into uncommon kinase domain duplications and rearrangementsSemantic proximity Read ↗

Defining the sensitivity landscape of EGFR variants to tyrosine kinase inhibitors.Semantic proximity Read ↗

In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.Semantic proximity Read ↗

Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants.Semantic proximity Read ↗

An unbiased in vitro screen for activating epidermal growth factor receptor mutationsSemantic proximity Read ↗

Preclinical characterization of mobocertinib highlights the putative therapeutic window of this novel EGFR inhibitor to EGFR exon 20 insertion mutationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.